Barclays raised the firm’s price target on Arcellx (ACLX) to $115 from $73 and keeps an Overweight rating on the shares following a transfer of ...

The six-piece version of our best less-expensive blow-dryer brush with multiple attachments is at an all-time low. It’s ...

Mom is involved in the therapy and doctors talk through each step and describe what they are working on. “They even show me ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The biotechnology-focused investor said its net asset value per share grew by 2.7% to 1,107.9 pence at September 30 from 1,078.9p at March 31, outperforming its benchmark the Nasdaq Biotechnology ...

Planegg/Martinsried, November 26, 2024.Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research ...

Roche RHHBY announced that it will acquire clinical-stage biopharmaceutical company Poseida Therapeutics, Inc. PSTX for $9 ...

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and ...

Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would ...

a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, ...